Octozi has successfully secured $3 million in seed funding, primarily driven by Swiss pharmaceutical investment, marking a notable deviation from the typical funding trajectory of US healthtech AI startups.
The funding round was led by Surface Ventures, with Remarkable Ventures participating alongside an earlier investment from Debiopharm’s venture arm. This early involvement from Debiopharm, particularly prior to engaging US investors, provided Octozi with valuable insights into European pharma's requirements for adopting AI solutions. The company's founder, Amit Patel, emphasized the potential of AI to enhance clinical trial processes, which traditionally rely heavily on human oversight and manual data management.
Octozi's platform integrates data from various clinical sources, employing over 100 tailored models to streamline data cleaning and improve accuracy. A peer-reviewed study highlighted the platform's ability to significantly enhance data-cleaning efficiency, achieving a sixfold increase in throughput and substantial cost savings during Phase III oncology trials. This performance was central to the swift closure of their funding round, showcasing the platform's tangible impact on clinical development timelines.
As the clinical data management market is projected to grow substantially in the coming years, Octozi's innovative approach positions it well within a landscape increasingly dominated by complex trials and stringent regulations. The company aims to leverage its funding to expand its team and further enhance its capabilities in clinical data management, contributing to the evolving intersection of AI and life sciences.